These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 6111989)

  • 1. Outcome and risks of ultra-long-term treatment with an oral neuroleptic drug. Relationship between perazine serum levels and clinical variables in schizophrenic outpatients.
    Pietzcker A; Poppenberg A; Schley J; Müller-Oerlinghausen B
    Arch Psychiatr Nervenkr (1970); 1981; 229(4):315-29. PubMed ID: 6111989
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Relationship between perazine serum concentration and clinical results in long-term treated schizophrenic outpatients (author's transl)].
    Pietzcker A; Müller-Oerlinghausen B; Schley J; Chaskel H; Poppenberg A; Urban R
    Arzneimittelforschung; 1978; 28(8):1302-3. PubMed ID: 37850
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Early serum levels of neuroleptics do not predict therapeutic response in schizophrenia.
    Gaebel W; Müller-Oerlinghausen B; Schley J
    Prog Neuropsychopharmacol Biol Psychiatry; 1992; 16(6):891-900. PubMed ID: 1355303
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prediction and evaluation criteria in perazine therapy of acute schizophrenics. Pharmacokinetic data.
    Breyer-Pfaff U; Brinkschulte M; Rein W; Schied HW; Straube E
    Pharmacopsychiatria; 1983 Sep; 16(5):160-5. PubMed ID: 6140695
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Comparison of higher-dose haloperidol therapy with perazine standard therapy in acute schizophrenic patients].
    Schmidt LG; Schüssler G; Kappes CV; Müller-Oerlinghausen B
    Nervenarzt; 1982 Sep; 53(9):530-6. PubMed ID: 6127637
    [No Abstract]   [Full Text] [Related]  

  • 6. [Effectiveness and tolerance of zotepine in a double-blind comparison with perazine in schizophrenic patients].
    Dieterle DM; Müller-Spahn F; Ackenheil M
    Fortschr Neurol Psychiatr; 1991 Sep; 59 Suppl 1():18-22. PubMed ID: 1683334
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prediction and evaluation criteria in perazine therapy of acute schizophrenics. Methodological considerations, sample population, and research variables.
    Rein W; Schied HW; Breyer-Pfaff U; Straube E
    Pharmacopsychiatria; 1983 Sep; 16(5):147-51. PubMed ID: 6140693
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Predictors of neuroleptic treatment response in acute schizophrenia: results of a treatment study with perazine.
    Gaebel W; Pietzcker A; Ulrich G; Schley J; Müller-Oerlinghausen B
    Pharmacopsychiatry; 1988 Nov; 21(6):384-6. PubMed ID: 2907645
    [No Abstract]   [Full Text] [Related]  

  • 9. Residual symptoms and P300 in schizophrenic outpatients.
    Juckel G; Müller-Schubert A; Gaebel W; Hegerl U
    Psychiatry Res; 1996 Nov; 65(1):23-32. PubMed ID: 8953658
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [The influence of antipsychotic therapy on the cognitive functions of schizophrenic patients].
    Tybura P; Mak M; Samochowiec A; Pełka-Wysiecka J; Grzywacz A; Grochans E; Zaremba-Pechmann L; Samochowiec J
    Psychiatr Pol; 2013; 47(4):567-78. PubMed ID: 24946464
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Experiences of schizophrenic patients in ambulatory care with oral neuroleptics--baseline for psychoeducational interventions].
    Hornung WP; Franzen U; Buchkremer G
    Schweiz Arch Neurol Psychiatr (1985); 1994; 145(4):18-22. PubMed ID: 7534435
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Auditory evoked potentials as possible predictors of outcome in schizophrenic outpatients.
    Hegerl U; Gaebel W; Gutzman H; Ulrich G
    Int J Psychophysiol; 1988 Aug; 6(3):207-14. PubMed ID: 2900230
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prediction and evaluation criteria in perazine therapy of acute schizophrenics: psychopathological results.
    Schied HW; Rein W; Straube E; Jung H; Breyer-Pfaff U
    Pharmacopsychiatria; 1983 Sep; 16(5):152-9. PubMed ID: 6140694
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [A differential effect profile of neuroleptic therapy of acute schizophrenic patients? Results of a clinico-naturalistic study].
    Schmidt LG; Siemetzki H
    Nervenarzt; 1988 Dec; 59(12):721-6. PubMed ID: 2905770
    [No Abstract]   [Full Text] [Related]  

  • 15. Neuroleptics normalize increased release of interleukin- 1 beta and tumor necrosis factor-alpha from monocytes in schizophrenia.
    Kowalski J; Blada P; Kucia K; Madej A; Herman ZS
    Schizophr Res; 2001 Jul; 50(3):169-75. PubMed ID: 11439237
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Zotepine versus perazine in patients with paranoid schizophrenia: a double-blind controlled trial of its effectiveness].
    Wetzel H; von Bardeleben U; Holsboer F; Benkert O
    Fortschr Neurol Psychiatr; 1991 Sep; 59 Suppl 1():23-9. PubMed ID: 1683336
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Can changes in eye-contacts predict therapeutic outcome in schizophrenic patients undergoing neuroleptic treatment? Results of a preliminary study.
    Meya U; Renfordt E
    Pharmacopsychiatry; 1986 Nov; 19(6):429-33. PubMed ID: 2879296
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Binding of perazine to alpha 1-acid glycoprotein.
    Schley J; Siegert M; Müller-Oerlinghausen B
    Eur J Clin Pharmacol; 1980 Nov; 18(6):501-4. PubMed ID: 6109633
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Autonomic nervous system differences as predictors of short-term outcome in schizophrenics.
    Straube ER; Schied HW; Rein W; Breyer-Pfaff U
    Pharmacopsychiatry; 1987 May; 20(3):105-10. PubMed ID: 2885864
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Changes in drug elimination under the influence of perazine therapy (author's transl)].
    Petruch F; Schüppel R; Breyer U
    Arzneimittelforschung; 1976; 26(6):1154-5. PubMed ID: 9113
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.